BetterLife Pharma (OTCMKTS:PVOTF) and Spruce Biosciences (NASDAQ:SPRB) Critical Survey

Spruce Biosciences (NASDAQ:SPRB) and BetterLife Pharma (OTCMKTS:PVOTF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Insider & Institutional Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 34.8% of BetterLife Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Spruce Biosciences and BetterLife Pharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91 million	18.17	-$53.04 million	($85.00)	-0.98
BetterLife Pharma	N/A	N/A	-$14.78 million	N/A	N/A

BetterLife Pharma has lower revenue, but higher earnings than Spruce Biosciences.

Profitability

This table compares Spruce Biosciences and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-305.39%	-168.01%
BetterLife Pharma	N/A	-205.15%	-147.23%

Analyst Ratings

This is a breakdown of recent ratings for Spruce Biosciences and BetterLife Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	4	3	1	2.44
BetterLife Pharma	0	0	0	0	0.00

Spruce Biosciences presently has a consensus price target of $178.88, suggesting a potential upside of 114.48%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Spruce Biosciences is more favorable than BetterLife Pharma.

Summary

Spruce Biosciences beats BetterLife Pharma on 7 of the 11 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About BetterLife Pharma

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.